MyoKardia Inc. (MYOK)

53.52
NASDAQ : Health Technology
Prev Close 53.55
Day Low/High 53.24 / 54.48
52 Wk Low/High 39.01 / 67.78
Avg Volume 375.30K
Exchange NASDAQ
Shares Outstanding 46.07M
Market Cap 2.47B
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna only went public in December, and is already creating a buzz.

Bears Are Doing an EKG Test on MyoKardia

Bears Are Doing an EKG Test on MyoKardia

A close below $44 will cause the bulls to throw in the towel and gains above $68 will do the same to the bears.

We Want Bad News, Bears: Cramer's 'Mad Money' Recap (Tuesday 10/30/18)

We Want Bad News, Bears: Cramer's 'Mad Money' Recap (Tuesday 10/30/18)

Jim Cramer says we actually want some bad news because definitive weaker news now drives stocks up and strong news takes them down.

MyoKardia Begins Patient Dosing In Phase 1b Clinical Study Of MYK-491 In Dilated Cardiomyopathy Patients

MyoKardia Begins Patient Dosing In Phase 1b Clinical Study Of MYK-491 In Dilated Cardiomyopathy Patients

Topline Results from First-in-Human Phase 1 Study of MYK-491 in Healthy Volunteers Demonstrated Tolerability and Increased Contractility

MyoKardia Presents Data From Study Of Machine Learning Algorithm Intended To Identify Obstructive Hypertrophic Cardiomyopathy Using A Wearable Biosensor

MyoKardia Presents Data From Study Of Machine Learning Algorithm Intended To Identify Obstructive Hypertrophic Cardiomyopathy Using A Wearable Biosensor

Digital Health Data from Substudy of PIONEER-HCM Presented in Late-Breaker at American Heart Association Scientific Sessions

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FORK, FUSB, LUK, PCTY, ROCK, XRAY Downgrades: AIV, CATM, CCRN, DRAD, EDGW, FOGO, MYOK, RIG, RVLT, SBRA, WRE Initiations: LKSD Read on to get TheStreet Quant Ratings' detailed report:

Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap (Mon 9/25/17)

Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap (Mon 9/25/17)

Jim Cramer looks at the high-flying FANG stocks, and says he likes these companies best when their prices return to earth.

MGM Resorts, Baozun, DowDuPont, Wynn Resorts: 'Mad Money' Lightning Round

MGM Resorts, Baozun, DowDuPont, Wynn Resorts: 'Mad Money' Lightning Round

Jim Cramer is bullish on MGM Resorts, Baozun, DowDuPont, and Wynn Resorts.

MyoKardia Unveils More Phase 2 Data on Heart Disease Treatment

MyoKardia Unveils More Phase 2 Data on Heart Disease Treatment

The South San Francisco, Calif. on Sept. 18 presented additional data from the first patient cohort of its Phase 2 study

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study Of Mavacamten (Formerly MYK-461) At The Heart Failure Society Of America's 21st Annual Scientific Meeting

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study Of Mavacamten (Formerly MYK-461) At The Heart Failure Society Of America's 21st Annual Scientific Meeting

New Positive Data on Secondary and Exploratory Endpoints Consistent with Previously Reported Topline Results

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I've Prepared for Hurricane Irma -- and a Market Pullback

As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.

How I'm Prepared for Irma -- and a Pullback

How I'm Prepared for Irma -- and a Pullback

As a Florida resident, I've learned the value of preparation and the 'Jensen Rules'.

TheStreet Quant Rating: C- (Hold)